RXRX | Ticker Profile - Titan Protect

RXRX

Recursion Pharmaceuticals, Inc.

Healthcare · Biotechnology · NMS

$3.32

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.7B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.61

Based on estimated future earnings — lower means cheaper

Rev Growth

-56.1%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-57.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$6.00

+81% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 7 analysts covering this stock

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

https://www.recursion.com

Country: United States Employees: 600 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.136

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0244

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.499

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-36.9%

Historical annualised return based on price data

Max Drawdown

-73.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

133

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.05

Moves slightly more than the broader market

52W High

$7.18

54% below the year high

52W Low

$2.77

20% above the year low

Avg Volume

13,565,408

Average daily shares traded — higher means easier to buy and sell

Short Ratio

14.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

36.8%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.16

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

7.06

Heavy leverage — higher financial risk if revenues decline

Current Ratio

5.47

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

5.15

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,985.6%

Profit from core operations before interest and tax

Free Cash Flow

$-177,795,632

Negative — the business is spending more than it generates

Revenue (TTM)

$66M

Total revenue over the last 12 months

Net Income

$-559,776,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$10.00

Target Median

$6.00

Target Low

$3.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go